Eugeroic
Eugeroics (originally, "eugrégorique" or "eugregoric"),[1] also known as wakefulness-promoting agents and wakefulness-promoting drugs, are a class of drugs that promote wakefulness and alertness.[2][3] They are used medically for the treatment of certain sleeping disorders, such as excessive daytime sleepiness and narcolepsy.[2][3] They generally have a very low addictive potential.[2][3]
Eugeroic | |
---|---|
Drug class | |
![]() The chemical structure of modafinil, the prototypical drug of this class. | |
Class identifiers | |
Synonyms | wakefulness-promoting agent wakefulness-promoting drug |
Use | Promote wakefulness and alertness |
ATC code | N06B |
In Wikidata |
The prototypical eugeroic is modafinil; other drugs in the class include adrafinil and armodafinil. Modafinil and armodafinil have been found to act as selective, weak, atypical dopamine reuptake inhibitors.[2][3]
Examples
Marketed
Discontinued
Never marketed
- CRL-40,940 (also called flumodafinil, bisfluoromodafinil, lauflumide)
- CRL-40,941
- Fluorenol
In Development
See also
Categories
► <a href='/wiki/Category:Drug_classes_defined_by_psychological_effects' title='Category:Drug classes defined by psychological effects'>Drug classes defined by psychological effects</a>
► <a href='/wiki/Category:Drugs_by_psychological_effects' title='Category:Drugs by psychological effects'>Drugs by psychological effects</a>
► <a href='/wiki/Category:Psychoactive_drugs' title='Category:Psychoactive drugs'>Psychoactive drugs</a>
References
- Milgram, Norton W.; Callahan, Heather; Siwak, Christina (2006). "Adrafinil: A Novel Vigilance Promoting Agent". CNS Drug Reviews. 5 (3): 193–212. doi:10.1111/j.1527-3458.1999.tb00100.x. ISSN 1080-563X.
- "Provigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. January 2015. Retrieved 16 August 2015.
- "Nuvigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. April 2015. Retrieved 16 August 2015.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.